Usual clinical dose of acetazolamide does not alter cerebral blood flow velocity.
Prior reports indicate that acetazolamide, an inhibitor of carbonic anhydrase, in moderate doses reduces symptoms of acute mountain sickness, and in large doses increases cerebral blood flow. The effect on flow is not known for a moderate dose, but were flow to increase, then increased cerebral oxygen delivery would be one mechanism of benefit from acetazolamide at high altitude. We utilized Doppler ultrasound in 8 volunteers to determine whether a usual acetazolamide dose (250 mg three times daily) would increase flow velocities in internal carotid and vertebral arteries. Acetazolamide during normoxia decreased pHa, PaCO2, and PETCO2, but baseline flow velocity remained unchanged. In 2 subjects without acetazolamide, voluntary hyperventilation decreased both PETCO2 and flow velocity. Both hypoxia and hypercapnia caused increases in arterial velocities. The increases were not altered by acetazolamide administration. In one subject, 1 g acetazolamide by acute i.v. injection induced an increase in flow velocity (40%) concomitant with a 5 mm Hg decrease in PETCO2, confirming prior reports using similar intravenous dose. In doses employed for prevention of acute mountain sickness, acetazolamide induced metabolic acidosis and may have prevented the fall in velocity usually associated with hypocapnia, but it neither increased baseline cerebral blood flow velocity nor velocity responses to hypoxia and hypercapnia. Benefit of acetazolamide at high altitude may relate to mechanisms other than increased cerebral blood flow.
Huang
S Y
SY
Cardiovascular Pulmonary Research Laboratory, University of Colorado Health Sciences Center, Denver 80262.
McCullough
R E
RE
McCullough
R G
RG
Micco
A J
AJ
Manco-Johnson
M
M
Weil
J V
JV
Reeves
J T
JT
D000086:Acetazolamide / Q000008:administration & dosage / Q000494:pharmacology*; D000328:Adult; D000532:Altitude Sickness / Q000188:drug therapy / Q000503:physiopathology; D001783:Blood Flow Velocity / Q000187:drug effects*; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D006801:Humans; D006935:Hypercapnia / Q000097:blood; D000860:Hypoxia / Q000097:blood; D008297:Male; D008875:Middle Aged; D012119:Respiration
D000086:Acetazolamide